|We wanted to share an update from the Department of US Health and Human Services around policies related to allocation, distribution, and administration efforts surrounding the current monoclonal antibody therapeutics available to combat the COVID-19 pandemic. |
Beginning Monday, September 13th HHS made a change to their distribution process to coordinate through a state/territory-coordinated system. The intent of this change is to maintain equitable distribution, both geographically and temporally providing states and territories with consistent, fairly distributed supply over the coming weeks and while the USG works to procure additional supply. Key to this change is that administration site (i.e. providers) will not be able to order mAbs directly from the distributor and must work with their state/territory to access the supply.
Weekly distribution amounts will be determined based on weekly reports of new COVID 19 cases and hospitalizations in addition to data on inventories. Weekly distribution determinations posted on phe.gov/mabs.